Hadassah

Hadassah Drug to Fight Fatty Liver Disease Progressing Well in US Clinical Trials

Thursday, Sep 3 2015

Clinical trials with a Hadassah-developed technology to treat fatty liver disease are moving forward in 25 medical centers, in the United States and Australia. Fatty liver disease, in its severe form—called non-alcoholic steatohepatitis (NASH)—can lead to cirrhosis and liver cancer and there are currently no other treatments available.

Among the US test sites are the Cleveland Clinic (Ohio), Duke Liver Center (Durham, NC), Baylor St. Luke's Medical Center (Houston, Tex), and University of Virginia (Charlottesville). The Australian sites include Westmead Hospital (Sydney) and The Alfred (Melbourne).

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product, being referred to as IMM-124E. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron. See http://www.hadassah.org/news-stories/fda-grants-approval-for-us.html

Immuron has also announced that it is beginning a United States Investor Roadshow, where it will showcase its technology platform and profile to US investment groups. The company reports that its clinical trials “are progressing well” and that “a recent Deutsche Bank review of the NASH market suggests that there is a worldwide market for NASH of between $35-40 billion.” The company further explains that “the high prevalence of Type 2 diabetes and obesity, which leads to NASH and other non-alcoholic fatty liver diseases, boosts the prevalence of NASH and its market growth.”

View the Roadshow presentation: http://www.immuron.com/index.php/download_file/-/view/142/

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Nov 14 2018

A Hassidic Mother’s Promise to Donate a Kidney: Mission Accomplished

A young girl named Esti had a best friend named Tali whose father had kidney disease. He passed away before a kidney transplant could save his life.

READ MORE ›
alt_text

Friday, Nov 9 2018

Children with Low Vision Receive Unique Care at Hadassah

“The vision of world-renowned Prof. Isaac Caesar Michaelson, former Director of the Hadassah Medical Organization’s Department of Ophthalmology, of creating in 1973 The Jerusalem Institute for the Prevention of Blindness still amazes me,” says Dr. Claudia Yahalom, current head of the renamed Michaelson Institute for Rehabilitation of Vision at Hadassah Hospital Ein Kerem.

READ MORE ›
alt_text

Tuesday, Nov 6 2018

Hadassah Staff Saves Seven-Year-Old From Deadly Scorpion Bite

The intensity of his cry alerted Elisha Alush’s parents that something serious had happened to their seven-year-old. He ran in from the backyard of their home near Jericho, north of Jerusalem, screaming, “My foot, my foot.” And then he lost consciousness.

READ MORE ›
alt_text

Thursday, Nov 1 2018

Hadassah Saves Soccer Fan’s Life in Newly Inaugurated Heart Center

Mickey Peretz, age 36, began his evening at a Beitar Jerusalem soccer game. Little did he know that he would end the evening being the first patient to receive a life-saving heart catheterization in Hadassah Hospital Ein Kerem’s brand new Irma and Paul Milstein Heart Center.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More